Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (197)

« Back to Publications

Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial

Kapulu MC. et al, (2026), Nature Medicine, 32, 178 - 185

B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings.

Bundi CK. et al, (2026), Frontiers in immunology, 17

B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings

Bundi CK. et al, (2025)

Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine.

McDaniel JR. et al, (2025), The Journal of experimental medicine, 222

R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial

Kibwana E. et al, (2025), Frontiers in Immunology, 16

Vaccine-induced responses to R21/Matrix-M – an analysis of samples from a phase 1b age de-escalation, dose-escalation trial

Bundi C. et al, (2025), Frontiers in Immunology, 16

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials

Venkatraman N. et al, (2025), The Lancet Microbe, 6, 100868 - 100868

R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18–45 years: an open-label, partially blinded, phase 1–2a controlled human malaria infection study

Venkatraman N. et al, (2025), The Lancet Microbe, 6, 100867 - 100867

A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies in patients with active Crohn's disease

Sanderson J. et al, (2025), eBioMedicine, 113, 105570 - 105570

The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E

Ali MS. et al, (2025), npj Vaccines, 10

Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines

Stockdale LK. et al, (2025), npj Vaccines, 10

Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial

Varley M. et al, (2025), BMJ Open, 15, e084345 - e084345

COMPARATIVE STUDY OF ANTIBODY EFFECTOR FUNCTIONS IN UK INDIVIDUALS AFTER VACCINATION EITHER WITH RTS,S AS01B OR R21 MATRIX-M ENROLLED INTO CONTROLLED HUMAN MALARIA INFECTION STUDIES

Munoz O. et al, (2025), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 112

Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults

Silman D. et al, (2024), Wellcome Open Research, 9, 734 - 734

Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine

McDaniel JR. et al, (2024)

Load More

1
2
3
4
5
6
7
...
»